<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               1     INDICATIONS AND USAGE<BR>               <BR>               <BR>                  <BR>                     <BR>                        Gleevec is a kinase inhibitor indicated for the treatment of:<BR>                        <BR>                           Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (1.1) <BR><BR>                           <BR>                           Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy (1.2)<BR><BR>                           <BR>                           Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) (1.3)<BR><BR>                           <BR>                           Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy (1.4)<BR><BR>                           <BR>                           Adult patients with myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements (1.5) <BR><BR>                           <BR>                           Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown (1.6)<BR><BR>                           <BR>                           Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown (1.7)<BR><BR>                           <BR>                           Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) (1.8) <BR><BR>                           <BR>                           Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST) (1.9)<BR><BR>                           <BR>                           Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST (1.10)<BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     1.1     Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML)<BR>                     <BR>                        Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase. <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     1.2     Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interferon-alpha (IFN) Therapy<BR>                     <BR>                        Patients with Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     1.3     Adult patients with Ph+ Acute Lymphoblastic Leukemia (ALL)<BR>                     <BR>                        Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     1.4     Pediatric patients with Ph+ Acute Lymphoblastic Leukemia (ALL)<BR>                     <BR>                        <BR>                           Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     1.5     Myelodysplastic/Myeloproliferative Diseases (MDS/MPD)<BR>                     <BR>                        Adult patients with myelodysplastic/ myeloproliferative diseases associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     1.6     Aggressive Systemic Mastocytosis (ASM)<BR>                     <BR>                        Adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation or with c-Kit mutational status unknown.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     1.7     Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL)<BR>                     <BR>                        Adult patients with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     1.8     Dermatofibrosarcoma Protuberans (DFSP)<BR>                     <BR>                        Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     1.9     Kit+ Gastrointestinal Stromal Tumors (GIST)<BR>                     <BR>                        Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors. <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     1.10     Adjuvant Treatment of GIST<BR>                     <BR>                        Adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive GIST. <BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>